DocMeetings

Low oxygen (hypoxia) is an emerging pathobiological hallmark of practically all solid tumors, acting as an independent prognostic factor in cancer patients. Canonically, hypoxia is transduced to the nucleus of cancer cells via hypoxia-inducible factor (HIF)- dependent transcriptional activation; however, recent evidence suggests that other HIF-independent pathways can complement or provide redundancy to these effects. We hereby discuss canonical and alternative oxygen sensing mechanisms implicated in therapy resistance and recurrence in cancer. In addition, we highlight recent evidence suggesting that conventional chemotherapy might act as an oxygen- independent HIF inducer in preclinical models of colon and breast cancer, thereby promoting therapy failure, metastasis and ultimately, mortality.

During the webinar, viewers will:

-Understand the current molecular oxygen-sensing framework in human cancer cells

-Hear a summary of the molecular and clinical implications of tumor hypoxia

-Explore recent evidence suggesting novel chemotherapeutic strategies targeting HIFs

-Have the opportunity to ask questions during the live broadcast